ASPET

JANUARY 25, 2024

Therapeutic vaccines containing aluminum adjuvants have been widely used in the treatment of tumors due to their powerful immune-enhancing effects. However, the neurotoxicity of aluminum adjuvants with different physicochemical properties have not been completely elucidated.

Vaccine 100

Vaccine Engineering Treatment 100

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . The company has already tested the treatment on 10 adults between the ages of 56-70, and 10 over 71. Conor Kavanagh. Source link.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

Eye on FDA

DECEMBER 15, 2021

We now have multiple vaccines – mRNA and traditional in the U.S. We have the emergence of monoclonal antibodies and protease inhibitors being utilized or being considered as treatments for various stages of disease. However there is also an alarming rise among people who have completed their primary vaccination.

Vaccine 72

Vaccine Nurses Virus Treatment 72

The Pharma Data

OCTOBER 30, 2020

More recently, the FDA announced regulatory approval for the first treatment for Covid-19. FDA approves first treatment for Covid-19. On October 22, the FDA approved the antiviral drug Veklury for use in adult and pediatric patients for the treatment of Covid-19 requiring hospitalization.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

Tebu Bio: Drug Discovery

APRIL 24, 2020

mRNA vaccines are developing very quickly with dozens of ongoing clinical trials against cancers or infectious diseases (e.g. Recombinant monoclonal antibody (mAB) based treatments have proven their efficacy. HIV or more recently SARS-Cov-2). Pre-clinical and clinical trials […]

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

SEPTEMBER 4, 2020

The findings have validated confidence in the experimental vaccine, the firm noted. Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, The company also announced the end of development of pimodivir, an investigational antiviral treatment for influenza A infection. Source link.

Vaccine 52

Vaccine Immune Response Disease Virus 52

The Pharma Data

APRIL 14, 2021

We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine. cases out of more than 6.8 Source link:[link].

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

The Pharma Data

JUNE 29, 2021

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. . ” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

Vaccine 52

Vaccine Disease International Treatment 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. per 1 million doses given to patients, according to the ACAAI.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. So researchers gave them an experimental vaccine called NeoVax. Unlike traditional vaccines, it is not a one-size-fits-all jab. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. The study included more than 10 years of public Facebook posts on the human papillomavirus (HPV) vaccine. 8 in the journal Vaccine.

Vaccine 52

Vaccine Doctors Virus Disease 52

The Pharma Data

SEPTEMBER 7, 2021

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School. The vaccine currently being tested stimulates the body’s immune system to produce antibodies to oxycodone.

Clinical Trials 52

Clinical Trials Vaccine Trials Medical Schools 52

The Pharma Data

SEPTEMBER 10, 2020

Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical trials being paused after a participant became ill. . We could still have a vaccine by the end of this year, early next year.”. It can be treated with steroids but the condition can be permanent. .

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JUNE 24, 2021

The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Secondary objectives are to describe immune responses produced by each of the vaccines.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. Professional. FRIDAY, Dec. FRIDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

MARCH 18, 2021

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Two doses of 3.75?g

Vaccine 52

Vaccine Trials Clinical Trials FDA 52

The Pharma Data

FEBRUARY 22, 2021

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. This new Phase 2 study will enable us to identify the final vaccine formulation for adults of all ages.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 30, 2020

30 December 2020 — AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. This is the first authorisation for this vaccine.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JUNE 24, 2021

This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. g doses of the COVID-19 vaccine.

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. The world has changed due to its impact – and the race to discover a vaccine is crucial for our return to normalcy.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

DECEMBER 11, 2020

Hacker groups in Russia and North Korea continue to mount cyberattacks against companies working on COVID-19 vaccines and treatments, Microsoft warned, calling on governments to take action against them. Among the targets, the majority are vaccine makers that have COVID-19 vaccines in various stages of clinical trials.

Vaccine 52

Vaccine Drug Development Government Clinical Research 52

The Pharma Data

SEPTEMBER 9, 2020

Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted after an unexplained illness was identified in one of the participants. It’s not actually the first time this has happened to the Oxford vaccine.”. Matt Fellows.

Vaccine 52

Vaccine Trials Government Treatment 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

SEPTEMBER 5, 2021

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). To date, AstraZeneca and its partners have supplied more than 1.1 Vaxzevria (ChAdOx1-S [Recombinant]).

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. .–( BUSINESS WIRE )– Moderna, Inc.,

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

DECEMBER 16, 2020

Moderna has revealed that it was impacted by last week’s cyberattack on the European Medicines Agency (EMA), during which hackers compromised agency computer systems and accessed vaccine regulatory submission documents for Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines. biotech firms ( DID , July 22 ). James Miessler.

Vaccine 52

Vaccine Regulations Government Research 52

The Pharma Data

MAY 5, 2022

The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS.

Vaccine 52

Vaccine FDA Pharmaceutical Companies Production 52

The Pharma Data

SEPTEMBER 4, 2020

Dr Moncef Slaoui, the leading doctor involved with Operation Warp Speed, has said it is unlikely a vaccine for the US will be ready by November. . But Slaoui did say that he believes a vaccine will be available by the end of the year, and could possibly vaccinate between 20 and 25 million people.

Doctors 52

Doctors Vaccine Licensing Licensing 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52

The Pharma Data

NOVEMBER 23, 2020

. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

AUGUST 21, 2020

Regeneron claims REGN-COV2, which is currently being studied in two Phase 2/3 clinical trials, provides a much-needed treatment option for Covid-19 that has the potential to prevent infection and thus slow down the spread of the pandemic on a global scale. McKesson supports OWS to centralize distributor of future Covid-19 vaccines.

Vaccine 52

Vaccine Clinical Trials Pharmacy Virus 52

The Pharma Data

JULY 23, 2021

government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country.

Vaccine 52

Vaccine Government Immune Response FDA 52

National Drug & Alcohol Research Centre Blog

FEBRUARY 24, 2022

Olivia Price It has been one year since the COVID-19 vaccine rollout commenced in Australia, and while vaccination rates initially lagged behind other countries, over 95% of Australians aged 12 years and older are now fully vaccinated. We tend to consider the remaining unvaccinated people a homogenous ‘anti-vax’ group.

Vaccine 52

Vaccine Drugs Disease Pharmaceuticals 52